Sergey Young, an investor and P.Diamandis: Longevity Course
Sergey Young and Peter Diamandis Back the Next Generation of Longevity Companies
Peter Diamandis, an engineer and entrepreneur, and Sergey Young, an investor, arrived at longevity from different directions. Diamandis built platforms that encouraged scientific innovation. Young spent years investing in companies working on healthier aging. Building a fund together looked like a natural next step.
The Right Partner at the Right Time
Sergey Young had already spent years backing longevity companies. He founded the Longevity Vision Fund before joining BOLD Capital Partners as a longevity venture partner. Later came BOLD Capital Partners. He also made time to write, speak, and explain why longevity was becoming more than a niche area of medical research.
That combination made him an obvious partner for Diamandis. One built global innovation platforms. The other focused on finding businesses that could turn scientific progress into products people might actually use.
In a Sergey Young biography, the BOLD Longevity Growth Fund marks a natural step rather than a change in direction.
Looking at Hundreds of Companies to Find a Few
The BOLD Longevity Growth Fund reviews roughly 200 longevity companies each year. Only about five make the cut. The numbers show how competitive the sector has become. More companies enter the longevity space every year, but only a small share meet the scientific and commercial standards the fund is looking for.
The opportunities come from all over healthcare, but the challenge isn't finding new ideas. One startup may focus on earlier diagnosis. Another develops AI tools for medical research. The fund’s goal is finding ideas backed by credible science along with a solid business approach.
Young tends to judge new technologies by the same standard. Can they improve everyday health in a meaningful way? That principle helps explain why the fund looks at technologies that support prevention, earlier diagnosis, and healthier aging.
The Partnership Fits the Broader Sergey Young Biography
People often discover Sergey Young as an investor. They usually find something else soon afterward. By the time the BOLD Longevity Growth Fund launched, Young had already established himself as one of the better-known investors focused on longevity. He founded the Longevity Vision Fund, later became a longevity venture partner at BOLD Capital Partners, and expanded his work beyond investing through educational initiatives, nonprofit projects, and his book The Science and Technology of Growing Young.
Beyond venture capital, Young helped launch XPRIZE Healthspan, supported educational programs, and wrote The Science and Technology of Growing Young. None of those projects asks readers to become scientists, but they explain why longevity research matters in everyday life.
That way of thinking shows up in the fund's investment choices. The team isn't waiting for one discovery to transform healthcare. It looks for technologies that solve real problems today and create a foundation for the next wave of progress.
That's one reason Young has consistently described longevity as a long-term investment theme. In healthcare, strong ideas often need years of development before they become products that doctors and patients can actually use.
Why Peter Diamandis Brings More Than a Well-Known Name
People often associate Diamandis with space or technology, but the thread running through his work has always been the same: helping promising scientific ideas reach a much wider audience. He had spent years around scientists and founders working on difficult, long-term problems, so longevity was less a new direction than a continuation of work he was already doing.
The fund doesn't limit itself to one corner of longevity. It considers companies working in different parts of healthcare, but the questions behind every investment stay much the same. Is science convincing? Can the team build a lasting business? Does the technology have a realistic chance of reaching patients?
The partnership brought together two investors with different backgrounds. Those backgrounds naturally complement each other. One brings experience evaluating healthcare businesses. The other has spent much of his career helping new technologies move beyond research labs and into the real world.
Their backgrounds also shape the way the fund operates. The team looks across different parts of healthcare rather than chasing one emerging trend, which leaves room to invest wherever the strongest ideas appear.
A Sector That Keeps Growing Up
The growth of the longevity sector has changed the job for investors. Every year, new startups enter the field with different ideas and different technologies. But more choice doesn't necessarily make decisions easier. Finding the few that can build lasting businesses takes careful evaluation as much as scientific expertise.
Young has spent years following the field as both an investor and an educator. Diamandis brings decades of experience building organizations around scientific innovation. Their partnership brings together two different kinds of experience, but the investment strategy is straightforward. The fund looks for companies that pair credible research with leadership capable of building lasting healthcare businesses.
The BOLD Longevity Growth Fund doesn't try to predict a single breakthrough. Instead, it looks across the longevity sector for companies with the science, leadership, and staying power to grow over time.
That approach fits naturally into Sergey Young's investor approach. Rather than betting on one idea, he has consistently focused on the longer path from scientific discovery to practical healthcare.
